|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM063055619 |
003 |
DE-627 |
005 |
20231221222951.0 |
007 |
tu |
008 |
231221s1984 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0210.xml
|
035 |
|
|
|a (DE-627)NLM063055619
|
035 |
|
|
|a (NLM)6328542
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Miller, P I
|e verfasserin
|4 aut
|
245 |
1 |
2 |
|a A single-blind comparison of oral and intravaginal treatments in acute and recurrent vaginal candidosis in general practice
|
264 |
|
1 |
|c 1984
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 29.06.1984
|
500 |
|
|
|a Date Revised 21.11.2013
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Sixty-three patients with acute or recurrent vaginal candidosis were allocated to treatment with either oral ketoconazole (200 mg twice daily for 5 days) or clotrimazole 100 mg vaginal tablets (one per night for 6 days). Analysis of the results of doctor and patient assessment showed that both treatments were highly effective in reducing the signs and symptoms of infection. Mycological cure rates were similar for both ketoconazole (82%) and clotrimazole (86%). The corresponding mycological relapse rates were 0% and 18%. A significantly higher number of patients expressed a preference for oral treatment (p less than 0.05)
|
650 |
|
4 |
|a Clinical Trial
|
650 |
|
4 |
|a Comparative Study
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Randomized Controlled Trial
|
650 |
|
7 |
|a Antifungal Agents
|2 NLM
|
650 |
|
7 |
|a Imidazoles
|2 NLM
|
650 |
|
7 |
|a Suppositories
|2 NLM
|
650 |
|
7 |
|a Clotrimazole
|2 NLM
|
650 |
|
7 |
|a G07GZ97H65
|2 NLM
|
650 |
|
7 |
|a Ketoconazole
|2 NLM
|
650 |
|
7 |
|a R9400W927I
|2 NLM
|
700 |
1 |
|
|a Humphries, M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Grassick, K
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 9 vom: 02., Seite 582-7
|w (DE-627)NLM023961570
|
773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:9
|g day:02
|g pages:582-7
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_72
|
912 |
|
|
|a GBV_ILN_120
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 3
|j 1984
|e 9
|b 02
|h 582-7
|